EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus )

Thomas M File iD, Julio A Ramirez iD, Ashley M Wilde iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.01087-24 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Thomas M File und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease, Summa Health, Akron, Ohio, USA. Hauptthemen laut MEDLINE: Tetracyclines, Community-Acquired Infections, Anti-Bacterial Agents, Soft Tissue Infections. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli. It also has activity against many nontuberculous mycobacterium (NTM) species. It is available both orally and intravenously, which allows for feasible switch therapy. This review will assess the antimicrobial activity, pharmacology, safety, and clinical efficacy of omadacycline and present the opinions of the authors on where to position omadacycline for clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TetracyclinesCommunity-Acquired InfectionsAnti-Bacterial AgentsSoft Tissue InfectionsMycobacterium abscessusMycobacterium Infections, NontuberculousSkin Diseases, BacterialHumansMethicillin-Resistant Staphylococcus aureusMicrobial Sensitivity TestsDrug Resistance, Multiple, BacterialStreptococcus pneumoniaeCommunity-Acquired Pneumonia

Stichwörter der Autor:innen

clinical useomadacyclinepneumoniaskin infections

Substanzen

TetracyclinesomadacyclineAnti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Disease, Summa Health, Akron, Ohio, USA.
  • Section of Infectious Diseases, Northeast Ohio Medical University, Rootstown, Ohio, USA.
  • Division of Infectious Diseases, University of Louisville, Louisville, Kentucky, USA.
  • Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky, USA.

ORCID-Profile: Thomas M File, Julio A Ramirez, Ashley M Wilde

Zitieren

APA

File, T. M., Ramirez, J. A., & Wilde, A. M. (2025). New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus ). Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01087-24

Vancouver

File TM, Ramirez JA, Wilde AM. New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus ). Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01087-24

BibTeX
@article{File2025,
  author = {File, Thomas M and Ramirez, Julio A and Wilde, Ashley M},
  title = {New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus )},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.01087-24}
}
Kostenlos starten →